|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C16H20BrN5O |
|||
| Molecular Weight | 378.27 | CAS No. | 1196541-47-5 | |
| Solubility (25°C)* | In vitro | DMSO | 75 mg/mL (198.27 mM) | |
| Ethanol | 10 mg/mL (26.43 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | GDC-0575 is a potent and selective CHK1 inhibitor with an IC50 of 1.2 nM. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro | GDC-0575 enhances the cytotoxicity of Cytarabine (AraC) in vitro[1]. |
||
| In vivo | GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor that results in tumor shrinkage and growth delay in xenograft models[2]. |
Protocol (from reference)
References
|
Selleck's GDC-0575 has been cited by 6 publications
| Endothelial activation and fibrotic changes are impeded by laminar flow-induced CHK1-SENP2 activity through mechanisms distinct from endothelial-to-mesenchymal cell transition [ Front Cardiovasc Med, 2023, 10:1187490] | PubMed: 37711550 |
| Endothelial activation and fibrotic changes are impeded by laminar flow-induced CHK1-SENP2 activity through mechanisms distinct from endothelial-to-mesenchymal cell transition [ Front Cardiovasc Med, 2023, 10:1187490] | PubMed: 37711550 |
| Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells [ J Exp Clin Cancer Res, 2022, 41(1):141] | PubMed: 35418303 |
| A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancer [ Biochem Biophys Res Commun, 2021, 584:7-14] | PubMed: 34753066 |
| Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma [ J Clin Invest, 2020, 139080] | PubMed: 33016928 |
| Small Molecule Inhibitors and a Kinase-Dead Expressing Mouse Model Demonstrate That the Kinase Activity of Chk1 Is Essential for Mouse Embryos and Cancer Cells [ Life Sci Alliance, 2020, 3(8):e202000671] | PubMed: 32571801 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.